Search Results - "Demarest, J."

Refine Results
  1. 1
  2. 2

    A broad range of Fab stabilities within a host of therapeutic IgGs by Garber, Ellen, Demarest, Stephen J.

    “…Although the functional properties of IgGs are well known, little has been published concerning the stability of whole IgG molecules. Stability is, however, a…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy by McCue, Amelia C, Demarest, Stephen J, Froning, Karen J, Hickey, Michael J, Antonysamy, Stephen, Kuhlman, Brian

    Published in mAbs (31-12-2024)
    “…T-cell engaging (TCE) bispecific antibodies are potent drugs that trigger the immune system to eliminate cancer cells, but administration can be accompanied by…”
    Get full text
    Journal Article
  5. 5

    Computationally Designed Bispecific Antibodies using Negative State Repertoires by Leaver-Fay, Andrew, Froning, Karen J., Atwell, Shane, Aldaz, Hector, Pustilnik, Anna, Lu, Frances, Huang, Flora, Yuan, Richard, Hassanali, Saleema, Chamberlain, Aaron K., Fitchett, Jonathan R., Demarest, Stephen J., Kuhlman, Brian

    Published in Structure (London) (05-04-2016)
    “…A challenge in the structure-based design of specificity is modeling the negative states, i.e., the complexes that you do not want to form. This is a difficult…”
    Get full text
    Journal Article
  6. 6
  7. 7

    Mutual synergistic folding in recruitment of CBP/p300 by p160 nuclear receptor coactivators by Wright, Peter E, Demarest, Stephen J, Martinez-Yamout, Maria, Chung, John, Chen, Hongwu, Xu, Wei, Dyson, H. Jane, Evans, Ronald M

    Published in Nature (London) (31-01-2002)
    “…Nuclear hormone receptors are ligand-activated transcription factors that regulate the expression of genes that are essential for development, reproduction and…”
    Get full text
    Journal Article
  8. 8

    Generalizable design parameters for soluble T cell receptor-based T cell engagers by Froning, Karen J, Sereno, Arlene, Huang, Flora, Demarest, Stephen J

    Published in Journal for immunotherapy of cancer (01-03-2022)
    “…While most biological and cellular immunotherapies recognize extracellular targets, T cell receptor (TCR) therapeutics are unique in their ability to recognize…”
    Get full text
    Journal Article
  9. 9

    Stability engineering of scFvs for the development of bispecific and multivalent antibodies by Miller, Brian R., Demarest, Stephen J., Lugovskoy, Alexey, Huang, Flora, Wu, Xiufeng, Snyder, William B., Croner, Lisa J., Wang, Norman, Amatucci, Aldo, Michaelson, Jennifer S., Glaser, Scott M.

    Published in Protein engineering, design and selection (01-07-2010)
    “…Single-chain Fvs (scFvs) are commonly used building blocks for creating engineered diagnostic and therapeutic antibody molecules. Bispecific antibodies (BsAbs)…”
    Get full text
    Journal Article
  10. 10

    Fine Details of IGF-1R Activation, Inhibition, and Asymmetry Determined by Associated Hydrogen /Deuterium-Exchange and Peptide Mass Mapping by Houde, Damian, Demarest, Stephen J.

    Published in Structure (London) (08-06-2011)
    “…The structural features of the asymmetric activated states of the insulin receptor family are still poorly understood. We investigated hydrogen/deuterium…”
    Get full text
    Journal Article
  11. 11

    An evaluation of Fuchs-Sondheimer and Mayadas-Shatzkes models below 14nm node wide lines by Smith, R. S., Ryan, E. T., Hu, C.-K., Motoyama, K., Lanzillo, N., Metzler, D., Jiang, L., Demarest, J., Quon, R., Gignac, L., Breslin, C., Giannetta, A., Wright, S.

    Published in AIP advances (01-02-2019)
    “…The applicability of the Fuchs-Sondheimer and Mayadas-Shatzkes scattering models below the 14nm node with wide interconnect trenches of variable aspect ratio…”
    Get full text
    Journal Article
  12. 12

    Emerging antibody combinations in oncology by Demarest, Stephen J., Hariharan, Kandasamy, Dong, Jianying

    Published in mAbs (01-07-2011)
    “…The use of monoclonal antibodies (mAbs) has become a general approach for specifically targeting and treating human disease. In oncology, the therapeutic…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17

    Building blocks for bispecific and trispecific antibodies by Wu, Xiufeng, Demarest, Stephen J.

    Published in Methods (San Diego, Calif.) (01-02-2019)
    “…Bispecific antibodies (BsAbs), which target two antigens or epitopes, incorporate the specificities and properties of two distinct monoclonal antibodies (mAbs)…”
    Get full text
    Journal Article
  18. 18

    Process Challenge in Analog Computing Hardware using Phase Change Memory (PCM) by Chan, Victor, Ok, I., Choi, S., Gordon, T., Arnold, N., Saraf, I., McDermott, S., Brew, K., Philip, T., Utomo, H., Tseng, W.-T., Silvestre, C., Li, N., Li, J., Demarest, J., Han, J.-P., Gasasira, A., Pujari, R., Saulnier, N., Teehan, S., Ahsan, Ishtiaq

    “…We discuss the process challenges such as the heater geometry effect, heater patterning processes and deep via formation. Based on the electrical data, we…”
    Get full text
    Conference Proceeding
  19. 19

    Selective Enablement of Dual Dipoles for near Bandedge Multi-Vt Solution in High Performance FinFET and Nanosheet Technologies by Bao, R., Watanabe, K., Zhang, J., Zhou, H., Sankarapandian, M., Li, J., Pancharatnam, S., Jamison, P., Southwick, R. G, Wang, M., Demarest, J. J, Guo, J., Loubet, N., Basker, V., Guo, D., Narayanan, V., Haran, B., Bu, H., Khare, M.

    Published in 2020 IEEE Symposium on VLSI Technology (01-06-2020)
    “…We report that n-dipole and p-dipole (dual dipoles) can be co-integrated to provide a more flexible volumeless multiple threshold voltage(multi-Vt) solution in…”
    Get full text
    Conference Proceeding
  20. 20

    Conserved amino acid networks involved in antibody variable domain interactions by Wang, Norman, Smith, William F., Miller, Brian R., Aivazian, Dikran, Lugovskoy, Alexey A., Reff, Mitchell E., Glaser, Scott M., Croner, Lisa J., Demarest, Stephen J.

    “…Engineered antibodies are a large and growing class of protein therapeutics comprising both marketed products and many molecules in clinical trials in various…”
    Get full text
    Journal Article